Previous 10 | Next 10 |
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis - DARZALEX FASPRO® Utilizing ENHANZE® Represents First and Only Approved Treatment...
Halozyme Therapeutics ([[HALO]] -5.7%) expects its FY21 revenue to range between $375-$395M (+40% to +45% Y/Y), shy of market consensus of $401.22M.The company expects a doubling in revenue from royalties, a significant increase in product sales related to API; however, this guidance exc...
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth - 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue - - 2021 Royalties Projected to Double versus Expected 2020 Royalties - - 2021 EP...
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive offic...
The European Commission ((EC)) has approved Roche's (RHHBY) Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with Halozyme Therapeutics' (HALO) ENHANZE technology, administered by subcutaneous injection for the treatment of patients with early and...
Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer -...
Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on the market and 11 trials ongoing using its technology, growing its royalty revenue and profits ...
We’re really intrigued by is Halozyme (HALO), which has a better mousetrap when it comes to drug delivery, asserts Mike Cintolo, editor of Cabot Growth Investor. For further details see: Halozyme- A "Better Mousetrap" in Drug Delivery
Halozyme Therapeutics (HALO) updated FY20 financial guidance reflecting the signing of a global collaboration and license agreement with Horizon Therapeutics.FY20 revenue guidance raised to $265M to $275M (vs. $250 to $260M earlier) growing 35-40% Y/Y growth indicating anticipated revenu...
Halozyme Raises Full Year 2020 Guidance - Raises 2020 Guidance to $265 Million to $275 Million in Revenues, Up from $250 Million to $260 Million, and EPS of $0.90 to $0.95, Up from $0.80 to $0.85 - PR Newswire SAN DIEGO, Nov. 23, 2020 SAN DIEGO , Nov. 23, 2...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...